Hosted on MSN1d
The Stages of Alzheimer's Disease
Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
clinicaltrialsarena2d
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...
The Pharma Letter2d
Sunbird Bio names industry vet, Richard Batrla, as CMO
Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and ...
Mild Cognitive Impairment Market Is Predicted To Advance At A CAGR Of 11.6% By 2034 Delveinsight
The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...
Hosted on MSN4d
The Alzheimer's Association says seniors in these Iowa counties have the highest rates of the disease
But earlier this year, the Food and Drug Administration fully greenlit the first drug proven to effectively treat the disease: lecanemab (sold under the brand name Leqembi), created by Eisai Inc. and ...
BioSpace5dOpinion
Opinion: The Cocktail Recipe That Will Cure Alzheimer’s
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
BioSpace5d
5 FDA Decisions to Watch in Q1
Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...